| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q3 2013 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| KURA ONCOLOGY INC | 15 | Q2 2024 | 7.2% |
| MORPHIC HOLDING INC | 15 | Q2 2024 | 6.9% |
| CELLDEX THERAPEUTICS INC NEW | 15 | Q2 2024 | 2.9% |
| IMMATICS N.V | 15 | Q2 2024 | 0.4% |
| ESTABLISHMENT LABS HLDGS INC | 14 | Q2 2024 | 8.3% |
| CEREVEL THERAPEUTICS HOLDINGS I | 13 | Q2 2024 | 6.1% |
| INARI MED INC | 13 | Q2 2024 | 6.4% |
| CYTOKINETICS INC | 13 | Q1 2024 | 2.6% |
| MADRIGAL PHARMACEUTICALS INC | 12 | Q2 2024 | 8.0% |
| ASCENDIS PHARMA A/S | 12 | Q4 2023 | 4.9% |
View Affinity Asset Advisors, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| NextCure, Inc. | June 27, 2024 | 1,672,839 | 6.0% |
| Context Therapeutics Inc. | February 13, 2024 | 328,817 | 2.1% |
| Spyre Therapeutics, Inc. | February 13, 2024 | 653,409 | 1.8% |
| Vincerx Pharma, Inc.Sold out | February 13, 2024 | 0 | 0.0% |
| Aeglea BioTherapeutics, Inc. | July 03, 2023 | 7,477,000 | 9.2% |
View Affinity Asset Advisors, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| SC 13G/A | 2024-08-14 |
| SC 13G | 2024-06-27 |
| 13F-HR | 2024-05-14 |
| SC 13G | 2024-05-07 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Affinity Asset Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.